Dissemin is shutting down on January 1st, 2025

Published in

Taylor and Francis Group, Leukemia & Lymphoma, 7(56), p. 2005-2012

DOI: 10.3109/10428194.2014.975800

Links

Tools

Export citation

Search in Google Scholar

18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.